Login to Your Account



Clinic Roundup


Friday, January 6, 2012

• Rigel Pharmaceuticals Inc., of South San Francisco, reported that two of its lead candidates have entered Phase I trials. R548, an oral JAK3 inhibitor, is being evaluated for transplant rejection and other systemic immune disorders. R333, a topical JAK/SYK inhibitor, is aimed at treating various phases of discoid lupus.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription